Intelligence Feed event · Equity · 2026-10-01

    Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial

    Question

    Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial

    Direct answer

    The Phase III SYNCHRONIZE-2 trial evaluated survodutide, a dual glucagon/GLP-1 receptor agonist, over a 76-week duration. The 13.1% mean weight loss delivers a significant separation from the 3.1% placebo response in an obesity and type 2 diabetes cohort. The positive readout strengthens the clinical profile for dual receptor agonists competing in the metabolic drug space, validating Zealand Pharma's underlying peptide platform.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/boehringer-and-zealand-report-13-1-weight-loss-in-phase-iii-trial-1eeb0d

    EQUITY
    Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial
    The Phase III SYNCHRONIZE-2 trial evaluated survodutide, a dual glucagon/GLP-1 receptor agonist, over a 76-week duration. The 13.1% mean weight loss delivers a significant separation from the 3.1% placebo response in an obesity and type 2 diabetes cohort. The positive readout strengthens the clinical profile for dual receptor agonists competing in the metabolic drug space, validating Zealand Pharma's underlying peptide platform.
    ZLDPY
    Impact
    77
    OCT 1
    SIG
    92%
    ZLDPY
    Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial
    The Phase III SYNCHRONIZE-2 trial evaluated survodutide, a dual glucagon/GLP-1 receptor agonist, over a 76-week duration. The 13.1% mean weight loss delivers a significant separation from the 3.1% placebo response in an obesity and type 2 diabetes cohort. The positive readout strengthens the clinical profile for dual receptor agonists competing in the metabolic drug space, validating Zealand Pharma's underlying peptide platform.
    → Statistically significant Phase III dual agonist efficacy data accelerates commercialization timelines for Zealand Pharma's royalty streams.
    Impact
    The Phase III SYNCHRONIZE-2 trial evaluated survodutide, a dual glucagon/GLP-1 receptor agonist, over a 76-week duration. The 13.1% mean weight loss delivers a significant separation from the 3.1% placebo response in an obesity and type 2 diabetes cohort. The positive readout strengthens the clinical profile for dual receptor agonists competing in the metabolic drug space, validating Zealand Pharma's underlying peptide platform.
    Affected
    ZLDPY
    Transmission
    Statistically significant Phase III dual agonist efficacy data accelerates commercialization timelines for Zealand Pharma's royalty streams.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYdrug candidate Phase III validation and future milestone/royalty monetizationUp1-5dZealand Pharma co-developed survodutide and announced Phase III SYNCHRONIZE-2 results.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month